Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Prime Medicine, Inc. - Common Stock (NQ:PRME)

3.415 +0.095 (+2.86%)
Streaming Delayed Price Updated: 12:54 PM EDT, Apr 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Prime Medicine, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Prime Medicine to Participate in Upcoming Investor Conferences
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Citi Downgrade Sparks Retail Chatter On Prime Medicine Amid Cash Runway Uncertainty ↗
The biotech firm announced a restructuring to focus on its liver disease programs while cutting costs and workforce amid ongoing development challenges. 
Via Stocktwits
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
This MongoDB Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday ↗
 
Via Benzinga
News headline image
6 Analysts Assess Prime Medicine: What You Need To Know ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Prime Medicine Announces Layoffs, CEO Transition: Retail Gets More Bullish ↗
The company said Keith Gottesdiener will step down as the chief executive, while CFO Allan Reine will succeed him. 
Via Stocktwits
Topics Workforce
News headline image
Prime Medicine Announces Strategic Restructuring to Focus on Opportunities in Large Genetic Liver Diseases, Cystic Fibrosis, and Partnered Programs Alongside CEO Leadership Transition
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Prime Medicine Announces Breakthrough Clinical Data Showing Rapid Restoration of DHR Positivity After Single Infusion of PM359, an Investigational Prime Editor for Chronic Granulomatous Disease
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Prime Medicine Reports First Quarter 2025 Financial Results and Provides Business Updates
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Cathie Wood's Ark Invest Offloads Uipath, Prime Medicine, And Repare Therapeutics ↗
On April 11th, 2025, Cathie Wood's Ark Invest sold shares in UiPath, Prime Medicine, and Repare Therapeutics, with notable gains and losses. 
Via Benzinga
News headline image
Why Prime Medicine Stock Was Climbing Higher This Week ↗
Via The Motley Fool
News headline image
Why Prime Medicine Stock Is Soaring Today ↗
Via The Motley Fool
News headline image
Prime Medicine Unveils Program for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Cathie Wood's Ark Invest Continues To Offload UiPath, Roblox: Loads Up On GitLab, Ibotta ↗
Ark Invest's Cathie Wood-led funds made significant trades involving GitLab, Intellia, Prime Medicine, UiPath, Ibotta, Roblox, Repare Therapeutics, and CareDx. 
Via Benzinga
News headline image
Prime Medicine Reports Full Year 2024 Financial Results and Provides Business Updates
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Prime Medicine to Present at TD Cowen 45th Annual Health Care Conference
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Prime Medicine to Present at 43rd Annual J.P. Morgan Healthcare Conference
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Prime Medicine Reports Third Quarter 2024 Financial Results and Provides Business Updates
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Prime Medicine to Participate in Upcoming Investor Conferences
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
12 High-Growth Stocks That Could Deliver Parabolic Returns ↗
These 12 innovative companies could deliver exponential returns over the next quarter century. 
Via The Motley Fool
News headline image
Prime Medicine Presents In Vivo Proof-of-Concept Data Highlighting Interim Preclinical Advances in its Wilson’s Disease Program and the Broad Potential of its Universal Liver-Targeted LNP at ESGCT 31st Annual Congress
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Why I Keep Buying These 14 Incredible Growth Stocks ↗
This diverse set of growth stocks offers tremendous opportunities in the fields of AI, space, biotech, and emerging industries. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Prime Medicine to Highlight New Preclinical Data, Including In Vivo Data in Wilson’s Disease, at Upcoming Scientific Meetings
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Why Prime Medicine Stock Soared Nearly 12% Higher on Monday ↗
Changes are afoot at the company, and investors welcomed them. 
Via The Motley Fool
News headline image
Dow Dips 300 Points; Emcore Shares Spike Higher ↗
 
Via Benzinga
Topics Stocks
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Crude Oil Moves Higher; Prime Medicine Shares Spike Higher ↗
 
Via Benzinga
News headline image
Prime Medicine, MINISO Group, Li Auto, Weibo And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.